Low dose sulphonylurea plus DPP4 inhibitor lower blood glucose and enhance beta cell function without hypoglycaemia.

Ruth Lorna Mary CordinerKhaled BedairAndrea Mari Ewan R Pearson

Published in: The Journal of clinical endocrinology and metabolism (2024)

Low dose sulphonylurea plus DPP4i has potent glucose lowering effect through augmentation of beta cell function. A double-blind randomised controlled trial would formalise efficacy and safety of this combination, which may avoid negative aspects of SU.

Keyphrases

blood glucose
low dose
glycemic control
high dose
type diabetes
study protocol
blood pressure
randomized controlled trial
clinical trial
anti inflammatory
soft tissue
metabolic syndrome
insulin resistance